Show simple item record

dc.contributor.authorHeckl, Dirk
dc.contributor.authorKowalczyk, Monika S.
dc.contributor.authorYudovich, David
dc.contributor.authorBelizaire, Roger
dc.contributor.authorPuram, Rishi V.
dc.contributor.authorMcConkey, Marie
dc.contributor.authorThielke, Anne
dc.contributor.authorAster, Jon C.
dc.contributor.authorRegev, Aviv
dc.contributor.authorEbert, Benjamin L.
dc.date.accessioned2015-04-22T18:42:07Z
dc.date.available2015-04-22T18:42:07Z
dc.date.issued2014-06
dc.date.submitted2014-04
dc.identifier.issn1087-0156
dc.identifier.issn1546-1696
dc.identifier.urihttp://hdl.handle.net/1721.1/96710
dc.description.abstractGenome sequencing studies have shown that human malignancies often bear mutations in four or more driver genes[superscript 1], but it is difficult to recapitulate this degree of genetic complexity in mouse models using conventional breeding. Here we use the CRISPR-Cas9 system of genome editing[superscript 2, 3, 4] to overcome this limitation. By delivering combinations of small guide RNAs (sgRNAs) and Cas9 with a lentiviral vector, we modified up to five genes in a single mouse hematopoietic stem cell (HSC), leading to clonal outgrowth and myeloid malignancy. We thereby generated models of acute myeloid leukemia (AML) with cooperating mutations in genes encoding epigenetic modifiers, transcription factors and mediators of cytokine signaling, recapitulating the combinations of mutations observed in patients. Our results suggest that lentivirus-delivered sgRNA:Cas9 genome editing should be useful to engineer a broad array of in vivo cancer models that better reflect the complexity of human disease.en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (P01 CA108631)en_US
dc.description.sponsorshipLeukemia & Lymphoma Society of America (Scholar Award)en_US
dc.description.sponsorshiptrategic Pharma-Academic Research Consortium for Translational Medicine (SPARC)en_US
dc.description.sponsorshipNational Human Genome Research Institute (U.S.). Centers of Excellence in Genomic Science (Grant 5P50HG006193-02)en_US
dc.description.sponsorshipBroad Institute of MIT and Harvarden_US
dc.language.isoen_US
dc.publisherNature Publishing Groupen_US
dc.relation.isversionofhttp://dx.doi.org/10.1038/nbt.2951en_US
dc.rightsCreative Commons Attribution-Noncommercial-Share Alikeen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/en_US
dc.sourcePMCen_US
dc.titleGeneration of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editingen_US
dc.typeArticleen_US
dc.identifier.citationHeckl, Dirk, Monika S Kowalczyk, David Yudovich, Roger Belizaire, Rishi V Puram, Marie E McConkey, Anne Thielke, Jon C Aster, Aviv Regev, and Benjamin L Ebert. “Generation of Mouse Models of Myeloid Malignancy with Combinatorial Genetic Lesions Using CRISPR-Cas9 Genome Editing.” Nature Biotechnology 32, no. 9 (June 22, 2014): 941–946.en_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biologyen_US
dc.contributor.mitauthorRegev, Aviven_US
dc.relation.journalNature Biotechnologyen_US
dc.eprint.versionAuthor's final manuscripten_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsHeckl, Dirk; Kowalczyk, Monika S; Yudovich, David; Belizaire, Roger; Puram, Rishi V; McConkey, Marie E; Thielke, Anne; Aster, Jon C; Regev, Aviv; Ebert, Benjamin Len_US
dc.identifier.orcidhttps://orcid.org/0000-0001-8567-2049
mit.licenseOPEN_ACCESS_POLICYen_US
mit.metadata.statusComplete


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record